摘要：

Methods and systems for identifying a cancer patient suitable for treatment with a PARP inhibitor. A 6-gene, 7-gene, and 8-gene predictor panels of genes that are predictive of patient resistance or sensitivity to PARP inhibitors such as Olaparib. An exemplary method may comprise: (a) measuring amplification or expression levels of a gene selected from the group consisting of BRCAI, BRCA2, H2AFX, MREIIA, TDG, XRCC5, CHEKI and CHEK2 in a sample from the patient; and (b) comparing the amplification or expression level of the gene from the patient with amplification or expression level of the gene in a normal tissue sample or a reference expression level, wherein an increase of amplification or expression of the gene encoding BRCA2, CHEKI or CHEK2 and/or a decrease of amplification or expression of the gene encoding BRCAI, H2AFX, MREIIA, TDG or XRCC5 indicates the patient will be suitable for treatment with the PARP inhibitor.

展开